Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
about
Biocompatible dialysis fluids for peritoneal dialysisTargeting cannabinoid signaling for peritoneal dialysis-induced oxidative stress and fibrosis.Infusion fluids contain harmful glucose degradation products.Citrate treatment reduces endothelial death and inflammation under hyperglycaemic conditions.Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over StudyEffects of biocompatible versus standard fluid on peritoneal dialysis outcomes."NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.Effect of the dialysis fluid buffer on peritoneal membrane function in childrenThe effect of low-GDP solution on ultrafiltration and solute transport in continuous ambulatory peritoneal dialysis patientsCardiovascular risk in the peritoneal dialysis patient.An update on peritoneal dialysis solutions.Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Effect of benfotiamine in podocyte damage induced by peritoneal dialysis fluid.Human RAGE antibody protects against AGE-mediated podocyte dysfunction.Dynamic O-linked N-acetylglucosamine modification of proteins affects stress responses and survival of mesothelial cells exposed to peritoneal dialysis fluids.Peritoneal dialysis tailored to pediatric needs.Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis.Low-GDP fluid (Gambrosol trio) attenuates decline of residual renal function in PD patients: a prospective randomized study.Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure.Nepsilon-(carboxymethyl)lysine, Nepsilon-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.Icodextrin decreases technique failure and improves patient survival in peritoneal dialysis patients.Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.Evaluation of glyoxal and methylglyoxal levels in uremic patients under peritoneal dialysis.Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.Complement Activation in Peritoneal Dialysis-Induced Arteriolopathy.Dialysate CA125 levels after 5 years on continuous peritoneal dialysis.Novel peritoneal dialysis solutions--what are the clinical implications?Effect of Scavenging Circulating Reactive Carbonyls by Oral Pyridoxamine in Uremic Rats on Peritoneal Dialysis.Buffer-dependent regulation of aquaporin-1 expression and function in human peritoneal mesothelial cells.Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.Neuronal damage and shortening of lifespan in C. elegans by peritoneal dialysis fluid: Protection by glyoxalase-1.Low Glucose Degradation Product Peritoneal Dialysis Regimen Is Associated With Lower Plasma EN-RAGE and HMGB-1 Proinflammatory Ligands of Receptor for Advanced Glycation End Products
P2860
Q24197836-0A32F0B6-D99A-494A-A2EB-54A26152F1EFQ33655394-D68B2791-52F5-4D8C-9DD5-5824BB605BB4Q33899086-8478DFDE-46E7-4624-A44F-270470BBE64BQ35703272-03B74173-E69B-494B-8252-15547869625DQ35904420-BFD6F058-8DC1-4C38-BDDA-CBBD39CAA682Q35982392-0F3615CB-7344-44E3-9AA6-2C7D98A773B2Q36475512-7A01408D-FD99-4BDE-8E10-3B49C31FCEC0Q36475639-F00977DA-F271-46F1-8CFA-1DB1995A55A4Q36492525-D7636806-41EB-4119-BEA3-0E7B527EC78DQ37000687-B8D28CA1-BC3F-4F55-A7AB-BFD2FB3B3D09Q37766750-92755D1F-D80F-437D-8949-42722FF02BF3Q37986357-8701489B-4E52-4771-BF28-15F03E3332FBQ38006722-C13F737B-66D8-40BE-8CAC-C3D7819F2356Q38895522-E3B781B9-60A0-4289-BA77-7E6FE846426FQ39363316-24DF7FC3-FF95-42C6-83AB-6F75A75F34BFQ41950856-A46FFFC6-8935-47D2-8150-34219910BEF7Q42226666-E2617464-8326-4C12-BB06-455A98B45C17Q42722791-70EA3B66-49B3-4532-8845-F892E07D7CC3Q43144754-99086FF7-8687-490F-8CDE-515F306D580CQ44042280-B2CC8A19-CA06-4702-B944-5A0017E06B18Q44805632-671D7790-D835-4CDE-A43A-F3F9E6E357A0Q44923131-8CB40C15-1384-4EF4-B3D5-720A4DE9C47DQ46101874-F48E94FD-8BF1-4FF2-8C7C-A0CB7A03C3A3Q46613130-3169984A-50EB-4820-875D-2A685BD37F7AQ48651768-66DDA5AE-A928-4626-830D-FBECDFB5B9BFQ50091275-E874A376-0667-4AE3-8FFC-696A2BEACD95Q51158179-3EBAA2F7-6B91-4BA0-91E0-C3DF87441B78Q52890076-DCD861F3-214C-4CD0-B456-F56D56FE6A27Q52927710-CF46021F-32EA-4690-ADCC-F4A8714FBB21Q53182076-C666C33F-BBAE-4FB5-B961-CC1601F1D54EQ53329399-ECE17FE5-9468-44FA-ADE1-40E1971DE1A3Q55075595-D008AE7B-7746-4CB6-961B-FF8316B48175Q57825113-143575BF-2ABD-4A52-8B12-EE71C6BEEC3C
P2860
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Glucose degradation products i ...... nter the systemic circulation?
@en
Glucose degradation products i ...... nter the systemic circulation?
@nl
type
label
Glucose degradation products i ...... nter the systemic circulation?
@en
Glucose degradation products i ...... nter the systemic circulation?
@nl
prefLabel
Glucose degradation products i ...... nter the systemic circulation?
@en
Glucose degradation products i ...... nter the systemic circulation?
@nl
P2093
P1433
P1476
Glucose degradation products i ...... nter the systemic circulation?
@en
P2093
Christoph Wanner
Eberhard Ritz
H Schneider
Kai Weigel
Martin Zeier
Reinhold Deppisch
Ulrike Haug
Vedat Schwenger
P304
P356
10.1046/J.1523-1755.2003.00705.X
P407
P50
P577
2003-01-01T00:00:00Z
P5875
P6179
1040033070